Overview

Behandling af Boern Med Foedevareallergi Med Omalizumab (Xolair)

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Food allergy is a common disease in childhood affecting up to 8% of children in Westernized countries. About 30 percent of children with food allergies are allergic to more than one food, most often milk, egg, wheat, peanut and tree nut. Peanut and hazelnut are common triggers of severe and potentially fatal food-induced anaphylactic reactions. Currently, there is no curative treatment for food allergy. Novel therapies for this potentially life-threatening condition are therefore much needed.
Phase:
Phase 4
Details
Lead Sponsor:
Carsten Bindslev-Jensen
Collaborators:
Novartis Pharmaceuticals
Thermo Fisher Scientific
Treatments:
Omalizumab